{"id":390970,"date":"2017-03-06T00:00:00","date_gmt":"2017-03-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2017-biopharma-age-related-macular-degeneration-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-16T11:27:15","modified_gmt":"2026-04-16T11:27:15","slug":"dlsfop0001-2017-biopharma-age-related-macular-degeneration-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfop0001-2017-biopharma-age-related-macular-degeneration-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Age-Related Macular Degeneration | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>Following the introduction of the anti-<abbr data-original-title=\"vascular endothelial growth factor\" title=\"\">VEGF<\/abbr>\u00a0therapies over a decade ago, the wet\u00a0<abbr data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr>market has been dominated by three therapies\u2014Roche\/Genentech\/Novartis\u2019s Lucentis, approved for wet\u00a0<abbr data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr>, Roche\/Genentech\/Chugai\u2019s Avastin, approved for cancer but commonly compounded and used off-label for wet\u00a0<abbr data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr>, and, most recently, Regeneron\/Bayer HealthCare\/Santen\u2019s Eylea, which has experienced strong and continued uptake at the expense of the other drugs within this class. Although the majority of\u00a0<abbr data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr>patients are diagnosed with the dry form of\u00a0<abbr aria-describedby=\"tooltip923093\" data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr><\/p>\n<p>age-related macular degeneration<\/p>\n<p>, management of this disease type is limited to minimally effective vitamin formulations because no prescription pharmacotherapies are approved for this large and underserved subpopulation. However, the pipeline features a growing number of novel agents targeting the advanced form of dry\u00a0<abbr data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr>\u00a0(i.e.,\u00a0<abbr data-original-title=\"geographic atrophy\" title=\"\">GA<\/abbr>), as well as therapies for wet\u00a0<abbr data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr>.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>Do\u00a0<abbr data-original-title=\"key opinion leader\" title=\"\">KOL<\/abbr>s perceive any differences between the mainstays Avastin, Eylea, and Lucentis? How is their use expected to change, if at all, over the next ten years?<\/li>\n<li>Biosimilar versions of Eylea and Lucentis are forecast to launch within the next ten years. What is the likely impact of these therapies on current and emerging\u00a0<abbr data-original-title=\"vascular endothelial growth factor\" title=\"\">VEGF<\/abbr>inhibitors?<\/li>\n<li>Therapies with longer dosing intervals than offered by current therapies represents a substantial unmet need in wet\u00a0<abbr data-original-title=\"age-related macular degeneration\" title=\"\">AMD<\/abbr>. To what extent are the emerging\u00a0<abbr data-original-title=\"vascular endothelial growth factor\" title=\"\">VEGF<\/abbr>\u00a0inhibitors Novartis\u2019s brolucizumab and Allergan\u2019s abicipar pegol expected to capitalize on this unmet need?<\/li>\n<\/ul>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390970","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390970\/revisions"}],"predecessor-version":[{"id":576841,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390970\/revisions\/576841"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}